Array Biopharma Inc (NASDAQ:ARRY) has entered into a clinical study collaboration deal with Pfizer Inc (NYSE:PFE) to investigate the efficacy and safety of numerous unique anti-cancer combinations, including company's binimetinib, with Pfizer's talazoparib, and avelumab. The firms have finalized this deal to assess the prospective advantages of combining molecularly...
Agile Therapeutics Inc (NASDAQ:AGRX) reported that the U.S. FDA released a complete response letter in response to the NDA resubmission for the firm’s investigational hormonal contraceptive patch named Twirla (AG200-15). The refiling of the NDA, which is looking for approval for Twirla was permitted for review earlier in 2017....
OHR Pharmaceutical Inc (NASDAQ:OHRP) a clinical-stage pharmaceutical firm advancing novel therapies for ophthalmic ailment, posted financial report for its fiscal year closed September 30, 2017. Dr. Jason Slakter, the CEO, reported that their primary objective at company continues to be the remarkable completion of the MAKO trial, their ongoing...
Dextera Surgical Inc (OTCMKTS:DXTR) a firm commercializing and developing the MicroCutter 5/80™ Stapler reported that it has submitted for Chapter 11 bankruptcy protection. At the same time, the company has entered into an asset purchase deal with Aesculap, Inc, an associate of B. Braun Group, for around $17.3 million. The...
OncoSec Medical Inc (NASDAQ:ONCS) reported the commencement of patient dosing in PISCES and KEYNOTE-695, the firm's global, multi-center, registration-based open-label Phase IIb clinical study. The trial will assess the combination of ImmunoPulse® IL-12 and pembrolizumab in people with unresectable metastatic melanoma who are progressing or have progressed on an...
Ekso Bionics Holdings Inc (NASDAQ:EKSO) reported the release of the EksoGT™ exoskeleton’s FES interface capability via an association with HASOMED. Previously applied for research, HASOMED’s RehaStim2 FES addition with EksoGT exoskeleton is CE Marked and is now offered for routine clinical application in Europe. The details Thomas Looby, the CEO and...
Achillion Pharmaceuticals Inc (NASDAQ:ACHN) reported the U.S. FDA has granted orphan drug status to ACH-4471 for the cure of people with C3 Glomerulopathy. C3G marks as a harmful renal ailment for which there is no permitted treatment. There are projected to be around 4,000 C3G subjects in the U.S.,...
Endocyte Inc (NASDAQ:ECYT) a biopharmaceutical entity advancing targeted therapeutics for tailored cancer treatment, reported that it has been chosen for inclusion to the NASDAQ Biotechnology Index®. The company’s addition to this index became effective on December, 18, 2017. The details The NASDAQ Biotechnology Index comprises securities of NASDAQ-listed firms that fulfill...
Idera Pharmaceuticals Inc (NASDAQ:IDRA) reported that the U.S. FDA has granted Fast Track status for the firm’s key development candidate IMO-2125 in together with Ipilimumab for the cure of “anti-PD-1” refractory metastatic melanoma in together with ipilimumab treatment. FDA’s Fast Track plan is intended to expedite the review and...
In the last trading session, the stock price of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) declined more than 1% to close the day at $1.62. The decline came at a share volume of 226,124 compared to average share volume of 860,784. More recently, the company posted financial report for the quarter...

Subscribe to our mailing list

* indicates required

Create a future where the human body can repair, restore, and rejuvenate itself

 

Trading Symbol

OTC: PLSI

The Next Big Global Cannabis Play